{"Title": "The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat", "Year": 2017, "Source": "Gen. Med.", "Volume": "19", "Issue": 4, "Art.No": null, "PageStart": 430, "PageEnd": 438, "CitedBy": 81, "DOI": "10.1038/gim.2016.122", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85017174833&origin=inward", "Abstract": "\u00a9 The Author(s) (2016).Purpose: Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the \u03b1-galactosidase A gene. Migalastat, a pharmacological chaperone, binds to specific mutant forms of \u03b1-galactosidase A to restore lysosomal activity. Methods: A pharmacogenetic assay was used to identify the \u03b1-galactosidase A mutant forms amenable to migalastat. Six hundred Fabry disease-causing mutations were expressed in HEK-293 (HEK) cells; increases in \u03b1-galactosidase A activity were measured by a good laboratory practice (GLP)-validated assay (GLP HEK/Migalastat Amenability Assay). The predictive value of the assay was assessed based on pharmacodynamic responses to migalastat in phase II and III clinical studies. Results: Comparison of the GLP HEK assay results in in vivo white blood cell \u03b1-galactosidase A responses to migalastat in male patients showed high sensitivity, specificity, and positive and negative predictive values (\u22650.875). GLP HEK assay results were also predictive of decreases in kidney globotriaosylceramide in males and plasma globotriaosylsphingosine in males and females. The clinical study subset of amenable mutations (n = 51) was representative of all 268 amenable mutations identified by the GLP HEK assay. Conclusion: The GLP HEK assay is a clinically validated method of identifying male and female Fabry patients for treatment with migalastat.", "AuthorKeywords": ["enzyme replacement therapy", "Fabry disease", "lysosomal storage disorder", "personalized medicine", "pharmacological chaperone"], "IndexKeywords": ["1-Deoxynojirimycin", "alpha-Galactosidase", "Biological Assay", "Cell Line", "Clinical Trials, Phase II as Topic", "Clinical Trials, Phase III as Topic", "Fabry Disease", "Female", "HEK293 Cells", "Humans", "Leukocytes", "Male", "Mutation", "Predictive Value of Tests", "Validation Studies as Topic"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85017174833", "SubjectAreas": [["Genetics (clinical)", "MEDI", "2716"]], "AuthorData": {"8325555900": {"Name": "Benjamin E.R.", "AuthorID": "8325555900", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57193858721": {"Name": "Della Valle M.C.", "AuthorID": "57193858721", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "26658806300": {"Name": "Wu X.", "AuthorID": "26658806300", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "26658473200": {"Name": "Katz E.", "AuthorID": "26658473200", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "8571115600": {"Name": "Pruthi F.", "AuthorID": "8571115600", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "55179085800": {"Name": "Williams H.", "AuthorID": "55179085800", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57190620848": {"Name": "Yu J.", "AuthorID": "57190620848", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57190620553": {"Name": "Kirk J.", "AuthorID": "57190620553", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57210542041": {"Name": "Barth J.", "AuthorID": "57210542041", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "57201233304": {"Name": "Barlow C.", "AuthorID": "57201233304", "AffiliationID": "60028901", "AffiliationName": "Parkinson's Institute and Clinical Center"}, "6701637395": {"Name": "Valenzano K.J.", "AuthorID": "6701637395", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "55304953200": {"Name": "Castelli J.", "AuthorID": "55304953200", "AffiliationID": "100457584", "AffiliationName": "Amicus Therapeutics"}, "15728320900": {"Name": "Lockhart D.J.", "AuthorID": "15728320900", "AffiliationID": "118452006", "AffiliationName": "TranscripTx, Inc."}, "57193842786": {"Name": "Bond S.", "AuthorID": "57193842786", "AffiliationID": "119178896", "AffiliationName": "Cambridge Biomedical"}, "57193843867": {"Name": "Bronfin B.", "AuthorID": "57193843867", "AffiliationID": "119178896", "AffiliationName": "Cambridge Biomedical"}, "7005292729": {"Name": "Bichet D.G.", "AuthorID": "7005292729", "AffiliationID": "60031078, 60009507", "AffiliationName": "Hopital du Sacre-Coeur, University of Montreal"}, "7006706457": {"Name": "Germain D.P.", "AuthorID": "7006706457", "AffiliationID": "60029937", "AffiliationName": "Division of Medical Genetics, University of Versailles, University Paris-Saclay"}, "7005600401": {"Name": "Giugliani R.", "AuthorID": "7005600401", "AffiliationID": "60014120", "AffiliationName": "Medical Genetics Service, HCPA/UFRGS"}, "55186237200": {"Name": "Hughes D.", "AuthorID": "55186237200", "AffiliationID": "60022148", "AffiliationName": "Royal Free Campus, University College London"}, "7006001698": {"Name": "Schiffmann R.", "AuthorID": "7006001698", "AffiliationID": "60017310", "AffiliationName": "Baylor Research Institute"}, "35392413900": {"Name": "Wilcox W.R.", "AuthorID": "35392413900", "AffiliationID": "60000928", "AffiliationName": "Department of Human Genetics, Emory Univ"}, "56686336000": {"Name": "Desnick R.J.", "AuthorID": "56686336000", "AffiliationID": "60012981", "AffiliationName": "Icahn School of Medicine at Mount Sinai"}}}